CIS Display

CIS display is an antibody selection tool and alternative to traditional phage display methods.

 

Unlike phage, yeast, or mammalian display, CIS display does not involve a biological system. This means that library sizes are less restricted and that larger libraries can be mined effectively.

Originally developed by a team at Isogenica including our current CEO Dr. Bill Eldridge, CIS display was first designed to interrogate high-diversity peptide libraries. Over time, this was extended very successfully to increasingly complex small format scaffolds such as Centyrins and VHHs.

 

 

 

 

 

 

 

 

 

 

Publications